Search all medical codes

Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of greater than 56 mg esketamine nasal self-administration

HCPCS code

Name of the Procedure:

Esketamine Nasal Self-Administration (greater than 56 mg) Supervised by Healthcare Provider
HCPCS Code: G2083

Summary

Esketamine nasal spray is used to treat severe and treatment-resistant depression. Under this procedure, a patient self-administers a dose of esketamine greater than 56 mg while being supervised by a physician or other qualified health care professional to ensure proper use and monitor for immediate side effects.

Purpose

Conditions Addressed:

  • Treatment-resistant depression (TRD)
  • Major depressive disorder (MDD) with acute suicidal ideation or behavior

Goals/Outcomes:

  • Rapid reduction in depressive symptoms
  • Enhanced mood stability
  • Prevention of depression-related hospitalization

Indications

Symptoms or Conditions Warranting the Procedure:

  • Persistent depressive symptoms despite using two or more antidepressants
  • Acute episodes of severe depression with suicidal thoughts or behaviors

Patient Criteria:

  • Adults diagnosed with TRD or MDD
  • Patients with no significant improvement from prior antidepressant treatment

Preparation

Pre-Procedure Instructions:

  • Patients should avoid food for at least 2 hours and liquids for 30 minutes before administration.
  • Disclose any current medications to the healthcare provider.

Diagnostic Tests:

  • Baseline blood pressure and pulse readings
  • Routine mental health evaluations

Procedure Description

  1. Introduction: The healthcare provider explains the procedure and assesses patient readiness.
  2. Preparation: The patient will be given a nasal spray device with the appropriate dose of esketamine (>56 mg).
  3. Administration:
    • The patient will self-administer the spray while seated under the supervision of the healthcare provider.
    • The patient needs to follow the specific inhalation instructions to ensure effective dosing.
  4. Monitoring:
    • The healthcare provider monitors the patient for at least 2 hours post-administration to watch for adverse effects like dissociation, increased blood pressure, and sedation.
  5. Post-procedure: Patients are evaluated for safety before being allowed to leave.

Equipment Used:

  • Esketamine nasal spray device
  • Blood pressure cuff and monitoring tools

Anesthesia or Sedation:

  • Not typically used; however, safety monitoring is essential.

Duration

The administration and subsequent monitoring typically take around 2 to 2.5 hours.

Setting

The procedure is performed in an outpatient clinic or a specialized treatment center with facilities to monitor patients for adverse reactions.

Personnel

  • Physician or other qualified healthcare professional
  • Nurses or medical assistants to assist in monitoring

Risks and Complications

Common Risks:

  • Dizziness
  • Nausea
  • Dissociation or feeling disconnected from reality
  • Increased blood pressure

Rare Complications:

  • Severe allergic reactions
  • Acute psychosis
  • Long-term dependency risks

Management:

  • Prompt medical intervention
  • Adjustments in dosing plans for future sessions

Benefits

Expected Benefits:

  • Rapid mood improvement often occurring within hours to days.
  • Increased overall quality of life and daily functioning.

Recovery

Post-Procedure Care:

  • Patients should have someone to drive them home.
  • Avoid operating machinery or engaging in potentially hazardous activities until the following day.
  • Follow-up appointments for additional doses or evaluations usually occur weekly or biweekly.

Recovery Time:

  • Most patients feel back to baseline within 12-24 hours.

Alternatives

Alternative Treatments:

  • Oral antidepressants
  • Traditional psychotherapy
  • Electroconvulsive therapy (ECT)
  • Transcranial magnetic stimulation (TMS)

Pros and Cons:

  • Oral Antidepressants: Safer but often less effective alone in TRD cases.
  • ECT/TMS: Invasive or time-consuming but can be highly effective.
  • Psychotherapy: Essential for long-term management but slower to show benefits.

Patient Experience

During Procedure:

  • Mild discomfort from nasal administration
  • Potential immediate sensations like dissociation or dizziness

After Procedure:

  • Varying levels of drowsiness or lethargy
  • Some residual dizziness or cognitive impairment

Pain Management:

  • Typically, no pain involved; comfort measures include resting in a calm environment and ensuring hydration.

Medical Policies and Guidelines for Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of greater than 56 mg esketamine nasal self-administration

Related policies from health plans

Similar Codes